Characterizing Longitudinal Outcomes in Adults With SMA Treated With Nusinersen
Latest Information Update: 27 Sep 2021
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 26 Oct 2020 New trial record